Use-results surveillance of TALYMUS ophthalmic suspension 0.1% (tacrolimus) in severe allergic keratoconjunctivitis
Latest Information Update: 31 Aug 2021
Price :
$35 *
At a glance
- Drugs Tacrolimus (Primary)
- Indications Allergic conjunctivitis; Keratoconjunctivitis
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
- 31 Aug 2021 New trial record